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Donepezil eﬀects on mood in patients with
schizophrenia and schizoaﬀective disorder

B R I E F R E PO R T

International Journal of Neuropsychopharmacology (2006), 9, 603–605. Copyright f 2005 CINP
doi:10.1017/S1461145705006115

S. Craig Risch1, Michael D. Horner2, Susan R. McGurk3, Simmy Palecko1,
John S. Markowitz2, Ziad Nahas2 and C. Lindsay DeVane2
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3
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Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind
cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaﬀective disorders, clinically stable on atypical antipsychotic medications. Patients had varying degrees
of depressive symptoms, ranging from no depression to clinically signiﬁcant depression. There was
no worsening or induction of depression in individual patients or the group as a whole. In addition there
was a statistically signiﬁcant antidepressant eﬀect in the group as a whole during the donepezil condition
and a clinically signiﬁcant antidepressant eﬀect in the patients with clinically signiﬁcant depressive
symptoms, although there were not enough depressed patients in the group to conclude that donepezil
may have antidepressant eﬀects. Thus, in this study, donepezil did not induce or worsen depressive
symptoms in schizophrenic and schizoaﬀective disorder patients.
Received 14 April 2005; Reviewed 13 June 2005; Revised 22 July 2005; Accepted 27 July 2005;
First published online 4 October 2005
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Introduction
Cummings (2000) has reviewed the demonstrated or
potential clinical utility of cholinesterase inhibitors as
‘cognitive enhancers ’ in a wide variety of neuropsychiatric illnesses. Studies of cholinesterase inhibitor augmentation of antipsychotics in schizophrenic
patients have yielded mixed results. Two placebocontrolled studies (Friedman et al., 2002; Tugal et al.,
2004) demonstrated no beneﬁts, while other studies
(Allen and McEvoy, 2002; Buchanan et al., 2003;
Risch et al., 2001; Rosse and Deutsch, 2002) have
demonstrated beneﬁts in Positive and Negative
Symptom Scale (PANSS) ratings and/or cognitive tests,
at least in some patients. These studies suggest
some heterogeneity in response among treatmentresistant patients, as is often seen with other augmentation agents in psychotic patients (Miller, 2004). In this
regard, we (Nahas et al., 2003; Risch et al., 2001) have
reported in double-blind placebo-controlled studies
that donepezil, when added to the therapeutic regimen
Address for correspondence : Dr S. Craig Risch, M.D., UCSF
Department of Psychiatry, 401 Parnassus Avenue Box F-0984,
San Francisco, CA 94143-0984, USA.
Tel. : (415) 476-7710 Fax : (415) 476-7320
E-mail : craigr@lppi.ucsf.edu

of patients treated for schizophrenia or schizoaﬀective
disorder receiving a variety of atypical antipsychotics,
may improve functional magnetic resonance imaging
(fMRI) measurements of blood ﬂow in the left frontal
lobe and the medial frontal cingulate.
However, as reviewed by Janowsky and Overstreet (1995) a large literature also suggests that the
administration of physostigmine, a reversible cholinesterase inhibitor, and other cholinomimetic agents may
induce a syndrome similar to clinical depression in
patients who have previously suﬀered from depressive
disorders. Thus, there has been some concern about
the relative safety of using cholinesterase inhibitor
medications in patients who have previously had or
currently have co-existing depressive symptoms.
We report preliminary results of the eﬀects of
donepezil on mood when used concurrently with
atypical antipsychotics in an augmentation strategy
for cognitive enhancement in patients with schizophrenia or schizoaﬀective disorder.

Methods
This was a Medical School Committee on Human
Subjects approved protocol and was performed in
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Table 1. Raw scores on the 31-item Hamilton Rating Scale
for Depression (HAMD) for all subjects at baseline,
on donepezil, and on placebo
Subject
no.

Donepezil

Placebo

0
26
6
9
3
27
4

0
12
1
2
6
14
9

0
21
12
8
5
19
2

Subject
no.

HAMD
baseline

Placebo

Donepezil

8
9
10
11
12
13

18
5
10
9
26
12

6
1
5
22
21
11

2
2
8
16
12
0

Subjects 1–7 received donepezil before placebo and subjects
8–13 received placebo before donepezil.
Subject number does not reﬂect the actual sequence of patient
order as this was a randomized, counterbalanced study.
Rather, the table presents together the subjects who received
donepezil ﬁrst (top) and those who received placebo ﬁrst
(bottom).

accordance with the ethical standards laid down in the
1964 Declaration of Helsinki. All subjects were legally
competent and gave written informed consent.
Thirteen psychiatrically stable patients (22–50 yr
old) with schizophrenia or schizoaﬀective disorder,
medicated with maintenance olanzapine, risperidone
or clozapine, received 5 mg/d donepezil for 6 wk
titrated to 10 mg/d for an additional 6 wk and
placebo for 12 wk, administered in a double-blind,
randomized, counterbalanced order. A trained clinician blinded to donepezil status administered the
31-item Hamilton Depression Rating Scale (HAMD)
at baseline, at 12 wk (after either placebo or donepezil), and at 24 wk (after the other condition). HAMD
scores at baseline ranged from 0 to 27.
Results
Scores on the 31-item HAMD during the three
conditions, baseline, donepezil augmentation and
placebo augmentation, are depicted in Table 1.
Comparing the change in HAMD scores, baseline–
donepezil (5.5¡7.9 S.D.) vs. baseline–placebo (1.7¡6.3),

95 % CI

Responsive

Cond

Mean

S.E.

Lower
Bound

Upper
Bound

1
2
3

12.024
6.476
10.286

2.688
1.658
2.342

6.109
2.827
5.131

17.939
10.125
15.440

there was a signiﬁcant overall group improvement
in the HAMD scores during the donepezil treatment
arm (t=2.38, p=0.035). Using repeated-measures
ANOVA, with HAMD scores as the dependent
variables and condition (baseline, donepezil, and
placebo) as the within-subjects factor, the results were
similarly signiﬁcant (F=4.54, p=0.026) (Table 2).
Most of these patients had no or only mild depressive
symptoms (HAMD scores <18) and no clinically
signiﬁcant induction or worsening of depressive
symptoms occurred in any of these patients during the
donepezil condition. However, four patients had
HAMD scores o18 (range 18–27) and all four of these
patients had a clinically signiﬁcant reduction of HAMD
scores and depressive symptoms (reductions ranged
from 13 to 17 points) during the donepezil condition.
Discussion
Our data are consistent with the report of Tugal
et al. (2004) that donepezil augmentation of antipsychotic pharmacotherapy does not induce depressive symptoms in non-depressed schizophrenics.
In their study 12 patients with schizophrenia on a
stable dose of high-potency typical antipsychotics
received 5 mg donepezil for 6 wk and placebo for
6 wk in a double-blind cross-over trial. In their
study they reported no change relative to placebo in
the PANSS, a variety of neurocognitive tests, and
in the Calgary Depression Scale during the donepezil
condition. Our study diﬀers from that of Tugal et al.
(2004) in that our patients received 10 mg donepezil
(rather than 5 mg) for 6 wk then 10 mg for 12 wk
(rather than 6 wk) and were on atypical antipsychotics
(rather than high-potency typical neuroleptics). In
the study of Tugal et al., 2004, patients with a Calgary
Depression Scale (Addington et al., 1992) score >6
were excluded and thus the study was not designed
or evaluable to determine the antidepressant eﬀects
of donepezil in depressed schizophrenics. In our
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Table 2. Repeated measures ANOVAs for each test
separately (baseline vs. donepezil vs. placebo) (n=13)
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study there were no exclusion criteria for the presence
of depressive symptoms and thus, as noted above,
we found a clinically signiﬁcant improvement in
HAMD scores in schizophrenic and schizoaﬀective
disorder patients with clinically signiﬁcant depression.
These study results, although limited to 13 subjects,
are also consistent with a report by Burt et al. (1999)
in which a treatment-refractory depressed bipolar
patient received a clinically signiﬁcant antidepressant
beneﬁt from donepezil augmentation. Thus, our
preliminary data suggest that the use of donepezil
with atypical antipsychotics in schizophrenic and
schizoaﬀective disorder patients neither induces or
worsens depressive symptoms (as also previously
reported by Tugal et al., 2004) and may even be
associated with a reduction or remission of depressive
symptoms ingin some subjects, as reported by Burt
et al. (1999) in a bipolar patient. It is important to
note that this study was not designed to test the antidepressant eﬀects of donepezil, but rather its relative
safety with respect to induction or worsening of
depressive mood symptoms in schizophrenic and
schizoaﬀective disorder subjects.
As detailed in Table 1, one of the four clinically
depressed subjects (subject no. 2) had clinically
signiﬁcant improvement in mood symptoms on
donepezil which relapsed when switched to placebo.
Subject no. 6 had some improvement in mood on
donepezil which worsened somewhat on placebo.
Subject no. 12 had a slight improvement in mood
on placebo which became clinically signiﬁcant when
switched to donepezil. Finally, subject no. 8 had
clinically signiﬁcant improvement in mood on
placebo which further improved on donepezil.
However, spontaneous remissions or ‘time in study’
eﬀects cannot be ruled out in these subjects, and the
sample size of clinically depressed subjects is small.
Thus, we conclude that in this study donepezil did
not induce or worsen depressive symptoms in
schizophrenic or schizoaﬀective disorder subjects.
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